Journal article
Priorities for developing respiratory syncytial virus (RSV) vaccines in different target populations
- Abstract:
-
Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract infection worldwide. but tThere is a monoclonal antibody, palivizumab, which can be used for prophylaxis, butis no licensed vaccine or clinically effective antiviral therapy. The development of an effective vaccine has been hampered over the last 50 years by a medical disastersignificant difficulties in the 1960s in which a formalin-inactivated vaccine led to increased severity of RSV disease following acquisition ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 478.5KB, Terms of use)
-
- Publisher copy:
- 10.1126/scitranslmed.aax2466
Authors
Bibliographic Details
- Publisher:
- American Association for the Advancement of Science
- Journal:
- Science Translational Medicine More from this journal
- Volume:
- 12
- Issue:
- 535
- Article number:
- eaax2466
- Publication date:
- 2020-03-18
- Acceptance date:
- 2019-09-25
- DOI:
- EISSN:
-
1946-6242
- ISSN:
-
1946-6234
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:1063243
- UUID:
-
uuid:2bb82122-b53f-4267-9c26-db6b4b286bea
- Local pid:
-
pubs:1063243
- Source identifiers:
-
1063243
- Deposit date:
-
2019-10-16
Terms of use
- Copyright holder:
- Drysdale et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
- Notes:
- This is the accepted manuscript version of the article. The final version is available from AAAS at: https://doi.org/10.1126/scitranslmed.aax2466
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record